Aberrant FGFR signaling has been implicated in GI cancer carcinogenesis especially in biliary tract, gastro-esophageal and colon cancers.
Debio 1347 is a selective oral inhibitor of FGFR 1-3 tyrosine kinases. It exhibited high antitumor activity in in vitro and in vivo tumor models with FGFR1-3 gene alterations. 1, 2 Debio 1347 showed encouraging preliminary clinical activity and manageable treatment-emergent adverse events (TEAE) in its first-in-human (FIH) phase 1 study (NCT1948297). Here we report results from the patients with GI cancers harboring an FGFR fusion.
CONTACT

FUZE is a worldwide clinical trial with participating countries in blue Recruitment started in February 2019
Ignacio Matos 1 , Lipika Goyal 2 , James M. Patients received Debio 1347 at doses between 60 and 150 mg orally daily in 28day cycles. Pharmacokinetics and pharmacodynamic were serially evaluated in blood, skin and/or tumor tissue.
The primary endpoints were to investigate the safety and to determine the MTD in the dose-escalation part of the study. Objective response rate (ORR) assessed per RECIST 1.1 and safety were the primary endpoints in expansion part. The median time on treatment was 24 weeks (range 4-47). The most common TEAEs were hyperphosphatemia, nausea, constipation, fatigue, alopecia and nail changes.
Debio 1347 -All doses (N=13) TEAEs (MedDRA Preferred Term) All Grades (%) Grade 3-4 (%)
Only Grade 3 TEAE was hyperphosphatemia in 4 patients (31%).
SAFETY
Eight-teen patients harboring FGFR1-3 fusions were enrolled as of March 11, 2019. Among 13 patients with GI cancers, 8 had intrahepatic cholangiocarcinoma (7 FGFR2 and one FGFR1 fusion), 1 had a gallbladder cancer (FGFR3 fusion), 2 had a colon cancer (FGFR2 fusion), and 2 had a gastric cancer (FGFR2 and FGFR3 fusion).
All had prior systemic therapy (mostly 2 or 3 lines; range 1-5). Partial responses were observed in 3 over 10 of the evaluable patients, 2 with a colon cancer and one with a cholangiocarcinoma; additional 6 patients had target lesions regression < 30% (SD).
EFFICACY CONCLUSION
DEBIO 1347 demonstrated promising antitumor activity in patients with GI cancers harboring an FGFR1-3 fusion with an acceptable initial safety profile.
The FUZE clinical trial of Debio 1347 for patients with advanced solid tumors harboring FGFR1-3 fusions includes patients with GI cancers (NCT03834220). 
